KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018

Pages: 32 Published: September 30, 2018 Report Code: GDHC054SP

  • Overview
  • Key Players
  • Contents
  • Listen
    https://www.ispeech.org

Questions topics:

› Opinion on abatacept failing to achieve its primary endpoint in its Phase III LN trial

› Views on the Phase III safety data for abatacept in LN

› Expectations regarding abatacept’s future development in lupus

› Opinion on ustekinumab’s ability to achieve partial improvements using SLEDAI-2K Responder Index-50

› Views on ustekinumab’s Phase III trial design

› Views on the absence of safety endpoints in the Phase III ustekinumab trial in SLE

› Perception of etanercept’s efficacy in discoid lupus erythematosus

› Opinion on etanercept’s safety data from the Phase II TARGET-DLE trial

Scope

› The insight briefing is based on Sociable Pharma’s analysis of primary research with our Lupus key opinion leaders (KOLs)

› In total, we conducted interviews with 10 KOLs:

– 5 Europe-based & 5 N. America-based

– Interviews performed during Aug 2018

> KOL data is analyzed to produce:

– Charts summarizing KOL opinions

– Chart call-outs of key information & details

– KOL quotes

– Summary of KOL reporting trends

– Insight from Sociable Pharma's analysts

Key Highlights

While most KOLs agreed that abatacept’s future in LN is uncertain, half of the KOLs highlighted that the drug has potential in lupus arthritis

Most KOLs highlighted that SLEDAI-2K Responder Index-50 data supports ustekinumab use in SLE

While most KOLs flagged that etanercept may exacerbate lupus features, half of the KOLs highlighted that etanercept has potential in lupus

Reasons to Buy

Combines Qualitative & semi-quantitative insight from key opinion leaders on Pipeline Therapy Data Presented at EULAR 2018

Includes insight & recommendations from our disease-specific healthcare analysts

Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus

Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion

Key Players

Janssen, BMS, Pfizer, Merck

Table of Contents

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

$2500

Can be used by individual purchaser only

$7500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.